• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

    1/23/24 4:09:22 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPIX alert in real time by email
    SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 6
    CUSIP No. 29668H708
    13G/A
     


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*
     




    ESSA Pharma Inc.
    (Name of Issuer)
     
    Common Shares
    (Title of Class of Securities)
     
    29668H708
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)



    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐
    Rule 13d-1(b)
    ☑
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes in the Form of Schedule 13G).





    CUSIP No. 29668H708
    13G/A
     

    1
    NAME OF REPORTING PERSON
    IRS IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
     
    Soleus Capital, LLC

    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
     
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, U.S.A.
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER

    4,327,622

    6
    SHARED VOTING POWER
     

    7
    SOLE DISPOSITIVE POWER

    4,327,622

    8
    SHARED DISPOSITIVE POWER
     

    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,327,622

    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW  (9) EXCLUDES CERTAIN SHARES*


    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.8% (1)
    12
    TYPE OF REPORTING PERSON*

    OO
             
    (1)  Based on a total of 44,142,088 Common Shares outstanding as of December 11, 2023 as set forth in ESSA Pharma, Inc.’s (the “Issuer”) Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 12, 2023.

    CUSIP No. 29668H708
    13G/A
     

    Item 1(a)
    Name of Issuer:
     
    ESSA Pharma, Inc.
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
     
    Suite 720, 999 West Broadway
     
    Vancouver, British Columbia, Canada, V5Z 1K5
       
    Item 2(a)
    Name of Person Filing:
     
    The Reporting Person is Soleus Capital, LLC. Additionally, information is included herein with respect to (i) Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership (“Soleus Master Fund”); (ii) Soleus Capital Special Opportunities Fund, L.P., a Delaware limited partnership (“Soleus Special Fund”), and (iii) Soleus Capital Group, LLC, a Delaware limited liability company (“Soleus Group”).  The Reporting Person is the sole general partner of each of Soleus Master Fund and Soleus Special Fund, and Soleus Group is the sole managing member of the Reporting Person.  Mr. Guy Levy is the sole managing member of Soleus Group and hereby disclaims beneficial ownership of shares held by any of the entities named herein.
       
    Item 2(b)
    Address of Principal Business Office or, if None, Residence:
       
     
    104 Field Point Road, 2nd Floor
     
    Greenwich, CT 06830
       
    Item 2(c)
    Citizenship:
       
     
    Delaware, U.S.A.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Common Shares
       
    Item 2(e)
    CUSIP Number:
       
     
    2966H708
       
    Item 3.
    If this Statement is filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is

     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Exchange Act;
           
     
    (b)
    ☐
    Bank as defined in Section 3(a) (6) of the Exchange Act;
           
     
    (c)
    ☐
    Insurance company as defined in Section 3(a) (19) of the Exchange Act;
           
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act;
           
     
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b) (1) (ii) (E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b) (1) (ii) (F);
           
     
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b) (1) (ii) (G);
           
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           


    CUSIP No. 29668H708
    13G/A
     
     
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act;
           
     
    (j)
    ☐
    Group, in accordance with Rule 13d-1(b) (1) (ii) (J).

     
    Not applicable.
       
    Item 4.
    Ownership.
       
     
     (a) Amount Beneficially Owned:  The Reporting Person is the general partner of each of Soleus Master Fund and Soleus Special Fund (the “Funds”), which collectively hold an aggregate of 4,327,622 Common Shares (the “Shares”) of the Issuer.  As the general partner of the Funds, the Reporting Person may be deemed to have sole power to vote or direct the vote and to dispose or to direct the disposition of the Shares.  As the sole general partner of the Reporting Person, Soleus Group may be deemed to have shared power to vote or to direct the vote and to dispose or direct the disposition the Shares.  The sole managing member of Soleus Group is Mr. Guy Levy, who may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares. Neither the filing of this Schedule 13G/A nor any of its contents shall be deemed to constitute an admission that Mr. Levy or Soleus Group is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed.
       
     
    (b)       Percent of Class:   9.8%, based on a total of 44,142,088 Common Shares outstanding as of December 11, 2023 as set forth in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 12, 2023..
       
     
    (c)       Number of shares as to which the Reporting Person has:  See Item 4(a) above.
       
    Item 5.
    Ownership of Five Percent or Less of a Class.
       
     
    Not Applicable
       
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
       
     
    Not Applicable
       
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     
    Not Applicable
       
    Item 8.
    Identification and Classification of Members of the Group.
       
     
    Not Applicable
       
    Item 9.
    Notice of Dissolution of Group.
       
     
    Not Applicable
       
    Item 10.
    Certifications.
       
     
    Not Applicable

     
    [The remainder of this page intentionally left blank]

    CUSIP No. 29668H708
    13G/A
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


    Date:  January 23, 2024


     
    Soleus Capital, LLC,
     
    By: Soleus Capital Group, LLC, its general partner
       
       
     
    /s/ Guy Levy
     
    Name: Guy Levy
     
    Title: Managing Member





     
    Get the next $EPIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPIX

    DatePrice TargetRatingAnalyst
    11/4/2024Buy → Hold
    Jefferies
    11/4/2024Outperform → Perform
    Oppenheimer
    11/4/2024$15.00 → $2.00Overweight → Neutral
    Piper Sandler
    6/26/2023$17.00Outperform
    Oppenheimer
    8/17/2021$36.00 → $22.00Outperform
    Oppenheimer
    More analyst ratings

    $EPIX
    Leadership Updates

    Live Leadership Updates

    See more
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    SEC Filings

    See more
    • ESSA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:04:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ESSA Pharma Inc.

      10-Q - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:00:30 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by ESSA Pharma Inc.

      SCHEDULE 13D - ESSA Pharma Inc. (0001633932) (Subject)

      4/24/25 8:56:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 7:32:27 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 4:04:37 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 6:56:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Financials

    Live finance-specific insights

    See more
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

      Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

      12/17/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Growth N V sold $12,018,409 worth of shares (7,879,583 units at $1.53), closing all direct ownership in the company (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/5/24 12:06:18 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,185 worth of shares (694 units at $6.03), decreasing direct ownership by 8% to 7,776 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      10/7/24 3:00:52 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,164 worth of shares (694 units at $6.00), decreasing direct ownership by 8% to 8,470 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      9/9/24 2:03:33 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      12/18/23 9:57:03 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/22/23 6:22:47 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/16/23 5:45:43 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ESSA Pharma downgraded by Jefferies

      Jefferies downgraded ESSA Pharma from Buy to Hold

      11/4/24 8:34:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Oppenheimer

      Oppenheimer downgraded ESSA Pharma from Outperform to Perform

      11/4/24 7:26:24 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously

      11/4/24 7:26:03 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care